Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

InnoCare Doses First Patient in Combination Trial of SHP2 Inhibitor

publication date: Mar 29, 2024

Beijing InnoCare Pharma has dosed the first patient in a China Phase Ib trial of ICP-189, its SHP2 allosteric inhibitor, in combination with ArriVent’s furmonertinib to treat advanced or metastatic non-small cell lung cancer (NSCLC). Furmonertinib is an approved highly brain-penetrant EGFR inhibitor. ICP-189 is a novel selective oral allosteric inhibitor of SHP2 (Src homology 2 domain containing protein tyrosine phosphatase), a non-receptor protein tyrosine phosphatase that is usually expressed in the cytoplasm of several tissues. Innocare’s ICP-189 has shown preliminary efficacy as a monotherapy. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital